Zevra Therapeutics announces MIPLYFFA , OLPRUVA presentations at SERGG

Zevra Therapeutics (ZVRA) announced that three posters on MIPLYFFA and one on OLPRUVA are being presented at the 42nd Annual Meeting of the Southeastern Regional Genetics Group, SERGG, taking place July 17-19, 2025, in Asheville, North Carolina. MIPLYFFA is approved in the U.S. for the treatment of Niemann-Pick disease type C. OLPRUVA is approved in the U.S. for the treatment of certain patients with urea cycle disorders. “The datasets on MIPLYFFA illustrate that its distinct mechanism of action precisely targets the underlying pathology of NPC, and this disease-modifying activity has led to sustained disease stabilization in patients undergoing treatment for multiple years. For OLPRUVA, we are presenting data on the ability for it to be administered via a gastrostomy tube, as this can play an important role in the management of UCD for some patients,” Adrian Quartel, M.D., FFPM, Zevra’s Chief Medical Officer.